Sisecam, the only global player operating across all key areas of glass and a pioneer in flat glass innovation, participated at GlassBuild America, one of North America’s leading trade shows for glass, windows and doors. Showcasing advanced glass solutions tailored to the needs and standards of the U.S. market, Sisecam once again demonstrated its global manufacturing strength with products focused on energy efficiency, sustainability and high performance.GlassbuildŞişecam Participated in GlassBuild America FairISTANBUL, Oct. 09, 2026 (GLOBE NEWSWIRE) — Sisecam, the only global company operating across all core areas of glass, participated at GlassBuild America, held in Las Vegas on September 23–25, showcasing its market-oriented architectural glass solutions. As a trusted global solutions partner, Sisecam stood out at...

SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) — TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced the pricing of its initial public offering of 8,333,334 shares of its common stock at an initial public offering price of $14.00 per share. All of the shares are being offered by TRexBio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $116.7 million. TRexBio’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 9, 2026, under the ticker symbol “TRXB”. The offering is expected to close on October 13, 2026, subject to the satisfaction of...

Perth, Western Australia, Oct. 09, 2026 (GLOBE NEWSWIRE) — QUARTERLY REPORT INVESTOR WEBINAR / CALL Perseus Mining Limited (ASX/TSX: PRU) is hosting an investor webinar and conference call to discuss its September 2026 Quarterly Results, which are anticipated for release around 8:30am AEDT on Tuesday, 27 October 2026. CALL DETAILSAustralia: Tuesday 27 October 2026Perth – 6:00amSydney/Melbourne – 9:00am Canada: Monday 26 October 2026Vancouver – 3:00pm Toronto – 6:00pm UK: Monday 26 October 2026London – 10:00pmRegister for the investor webinar at: https://us02web.zoom.us/webinar/register/WN_5JPqtLq5QVOV1wqjG1Mn1g After registering, you will receive a confirmation email containing information about joining the webinar. To join the webinar via telephone, please use one of the following numbers and enter the Webinar ID: 884 8441...

FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) — Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases, announced today the pricing of its upsized initial public offering of 3,750,000 shares of its common stock at an initial public offering price of $12.00 per share. The gross proceeds to Retension from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Retension, are expected to be $45.0 million. All shares of common stock are being offered by Retension. Retension has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of its common stock at the initial public offering...

Star ratings support Clover’s continued ability to offer market-leading and low out-of-pocket costs for members WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medicaid Services (“CMS”) has awarded its PPO Medicare Advantage (“MA”) plans a rating of 5 Stars and its HMO MA plan a rating of 4.5 Stars for 2027, which will affect payment year 2028. Through the first half of 2026, Clover Health grew Medicare Advantage membership ~48% year-over-year to more than 157,000 members, with ~98% enrolled in its wide-network PPO plans. At 5 Stars, Clover’s PPO plans will be able to enroll beneficiaries year round. Each year, CMS assigns Star ratings to Medicare Advantage and Part D contracts on...

Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well-tolerated safety profile NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authoritiesZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results of RAPIDe-3, a phase 3, global, randomized, double-blind, placebo-controlled crossover study evaluating...

67MW expansion brings Bitdeer AI’s secured AI Cloud data center capacity to approximately 273.5MW, or approximately 78% of its target of up to 350MW to be delivered by the first quarter of 2028 SINGAPORE, Oct. 08, 2026 (GLOBE NEWSWIRE) — Bitdeer AI, part of Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer AI”), an AI neocloud service provider and preferred NVIDIA Cloud Partner, today announced that it has entered into a 10-year data center services agreement for A901, a 67MW AI Cloud data center campus in Malaysia. A901 establishes a third Malaysian hub for Bitdeer AI alongside Cyberjaya and Johor, and will be engineered for liquid-cooled, rack-scale NVIDIA GB300 NVL72 systems serving next-generation enterprise AI workloads. Delivery of A901 capacity is targeted to commence in the first quarter of 2027, with delivery of the full...

CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) announces a production update as well as plans to release its Q3 2026 financial & operating results on Friday, November 6, 2026. Q3 2026 Production Update(1)(2)Q3 2026 average production was 83,259 boe/d. Production in September was supported primarily by increased production from near-field exploration success at LLA-111 in the Eastern Llanos. Parex is reiterating its H2 2026 average production guidance of 82,000 to 91,000 boe/d(3), with production growth from current levels expected to be driven by the November addition of approximately 7,000 bbl/d (net) from the Ecopetrol partnership in the Magdalena, alongside continued success at LLA-111.boe/d For the three months ended September 30, 2026Llanos 58,290LLA-34 18,813Magdalena 5,309Putumayo 847Average...

ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) — Lithium Argentina AG (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) will release its third quarter 2026 earnings results before market open on Tuesday, November 10, 2026. The Company will hold a webcast and conference call to discuss its third quarter 2026 results on Tuesday, November 10, 2026 at 10:00 a.m. ET. The webcast will be accessible on the Investor Relations section of the Company website at https://investors.lithium-argentina.com/news-events/events. Webcast Details: Event Title: Lithium Argentina Third Quarter 2026 Earnings Conference CallEvent Date: November 10, 2026Start Time: 10:00 AM Eastern time (US and Canada) Attendee URL: https://events.q4inc.com/attendee/520176896 Replay Information:A webcast replay will be available following the conclusion of...